Shenzhen Neptunus Bioengineering Co Ltd (000078) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shenzhen Neptunus Bioengineering Co Ltd (000078) has a cash flow conversion efficiency ratio of -0.006x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-16.37 Million ≈ $-2.40 Million USD) by net assets (CN¥2.85 Billion ≈ $416.32 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Shenzhen Neptunus Bioengineering Co Ltd balance sheet quality to measure how much of total assets are equity-financed.
Shenzhen Neptunus Bioengineering Co Ltd - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Shenzhen Neptunus Bioengineering Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 000078 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Shenzhen Neptunus Bioengineering Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shenzhen Neptunus Bioengineering Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Xingtong Shipping Co. Ltd.
SHG:603209
|
N/A |
|
Shenzhen Strongteam Decoration Engineering Co Ltd
SHE:002989
|
0.151x |
|
Tiptree Inc
NASDAQ:TIPT
|
-0.024x |
|
Drugs Made In America Acquisition II Corp. Ordinary Shares
NASDAQ:DMII
|
0.000x |
|
VersaBank
TO:VBNK
|
0.051x |
|
Sinovac Biotech Ltd
NASDAQ:SVA
|
0.013x |
|
Alok Industries Limited
NSE:ALOKINDS
|
-0.010x |
|
New York Mortgage Trust Inc
NASDAQ:NYMT
|
0.028x |
Annual Cash Flow Conversion Efficiency for Shenzhen Neptunus Bioengineering Co Ltd (1998–2025)
The table below shows the annual cash flow conversion efficiency of Shenzhen Neptunus Bioengineering Co Ltd from 1998 to 2025. For the full company profile with market capitalisation and key ratios, see Shenzhen Neptunus Bioengineering Co Ltd (000078) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥2.18 Billion ≈ $318.49 Million |
CN¥104.39 Million ≈ $15.28 Million |
0.048x | +244.96% |
| 2024-12-31 | CN¥2.84 Billion ≈ $416.13 Million |
CN¥39.54 Million ≈ $5.79 Million |
0.014x | +114.30% |
| 2023-12-31 | CN¥4.22 Billion ≈ $617.14 Million |
CN¥-410.19 Million ≈ $-60.02 Million |
-0.097x | -823.85% |
| 2022-12-31 | CN¥6.11 Billion ≈ $894.15 Million |
CN¥-64.33 Million ≈ $-9.41 Million |
-0.011x | -108.88% |
| 2021-12-31 | CN¥7.31 Billion ≈ $1.07 Billion |
CN¥866.12 Million ≈ $126.74 Million |
0.119x | -46.22% |
| 2020-12-31 | CN¥7.49 Billion ≈ $1.10 Billion |
CN¥1.65 Billion ≈ $241.53 Million |
0.220x | -23.74% |
| 2019-12-31 | CN¥7.85 Billion ≈ $1.15 Billion |
CN¥2.27 Billion ≈ $331.97 Million |
0.289x | +282.22% |
| 2018-12-31 | CN¥7.16 Billion ≈ $1.05 Billion |
CN¥-1.14 Billion ≈ $-166.11 Million |
-0.159x | +57.83% |
| 2017-12-31 | CN¥6.47 Billion ≈ $946.76 Million |
CN¥-2.43 Billion ≈ $-356.01 Million |
-0.376x | -47.65% |
| 2016-12-31 | CN¥5.88 Billion ≈ $860.13 Million |
CN¥-1.50 Billion ≈ $-219.06 Million |
-0.255x | -703.04% |
| 2015-12-31 | CN¥2.14 Billion ≈ $313.60 Million |
CN¥90.51 Million ≈ $13.24 Million |
0.042x | +164.08% |
| 2014-12-31 | CN¥1.78 Billion ≈ $260.85 Million |
CN¥-117.48 Million ≈ $-17.19 Million |
-0.066x | -1.10% |
| 2013-12-31 | CN¥1.89 Billion ≈ $276.27 Million |
CN¥-123.07 Million ≈ $-18.01 Million |
-0.065x | +15.69% |
| 2012-12-31 | CN¥1.06 Billion ≈ $154.67 Million |
CN¥-81.73 Million ≈ $-11.96 Million |
-0.077x | +60.55% |
| 2011-12-31 | CN¥971.04 Million ≈ $142.09 Million |
CN¥-190.33 Million ≈ $-27.85 Million |
-0.196x | -531.98% |
| 2010-12-31 | CN¥902.62 Million ≈ $132.08 Million |
CN¥40.96 Million ≈ $5.99 Million |
0.045x | -84.77% |
| 2009-12-31 | CN¥692.59 Million ≈ $101.35 Million |
CN¥206.34 Million ≈ $30.19 Million |
0.298x | +13.26% |
| 2008-12-31 | CN¥780.79 Million ≈ $114.25 Million |
CN¥205.39 Million ≈ $30.05 Million |
0.263x | +369.89% |
| 2007-12-31 | CN¥903.62 Million ≈ $132.23 Million |
CN¥50.59 Million ≈ $7.40 Million |
0.056x | -10.00% |
| 2006-12-31 | CN¥868.76 Million ≈ $127.13 Million |
CN¥54.04 Million ≈ $7.91 Million |
0.062x | +39.82% |
| 2005-12-31 | CN¥805.26 Million ≈ $117.83 Million |
CN¥35.82 Million ≈ $5.24 Million |
0.044x | +205.31% |
| 2004-12-31 | CN¥1.45 Billion ≈ $212.47 Million |
CN¥-61.34 Million ≈ $-8.98 Million |
-0.042x | -114.41% |
| 2003-12-31 | CN¥1.44 Billion ≈ $211.22 Million |
CN¥-28.44 Million ≈ $-4.16 Million |
-0.020x | +63.65% |
| 2002-12-31 | CN¥2.06 Billion ≈ $301.91 Million |
CN¥-111.83 Million ≈ $-16.36 Million |
-0.054x | -29.21% |
| 2001-12-31 | CN¥1.97 Billion ≈ $288.97 Million |
CN¥-82.84 Million ≈ $-12.12 Million |
-0.042x | +90.83% |
| 2000-12-31 | CN¥238.75 Million ≈ $34.94 Million |
CN¥-109.25 Million ≈ $-15.99 Million |
-0.458x | -367.67% |
| 1999-12-31 | CN¥205.69 Million ≈ $30.10 Million |
CN¥-20.13 Million ≈ $-2.95 Million |
-0.098x | +54.56% |
| 1998-12-31 | CN¥177.08 Million ≈ $25.91 Million |
CN¥-38.13 Million ≈ $-5.58 Million |
-0.215x | -- |
About Shenzhen Neptunus Bioengineering Co Ltd
Shenzhen Neptunus Bioengineering Co., Ltd. engages in the research and development, production, and sale of Chinese patent medicines, infusion products, and western medicine preparations in China. The company provides oryzanol tablets, chlorpheniramine maleate tablets, estazolam tablets, and rifampicin capsules, as well as technical support for generic drug quality consistency evaluation and othe… Read more